Neuronetics (STIM) Q4 2024: 11% Revenue Growth Driven by Greenbrook Acquisition and Better Me Provider Expansion
Neuronetics advanced its vertically integrated mental health platform with the Greenbrook acquisition and expanded its Better Me Provider (BMP) program, driving an 11% revenue increase in Q4 2024. Operational synergies and program adoption underpin confidence in reaching cash flow positivity by Q3 2025. The company’s 2025 guidance reflects growth ambitions balanced with margin pressures from clinic integration.
Summary
- Integration Momentum: Greenbrook acquisition accelerates scale and operational synergies across 95 clinics.
- Program-Driven Growth: BMP program boosts patient throughput, enhancing system utilization and care standards.
- Financial Discipline: Cost synergies and capital raise support path to cash flow positive in Q3 2025.
Business Overview
Neuronetics is a medical technology company specializing in neurohealth therapies, primarily through its NeuroStar Advanced Therapy System, a transcranial magnetic stimulation (TMS) treatment for major depressive disorder and related conditions. The company generates revenue through system sales, treatment sessions, and clinic operations, the latter significantly expanded by its recent acquisition of Greenbrook TMS, which operates 95 treatment centers across the United States.
Performance Analysis
In the fourth quarter of 2024, Neuronetics reported total revenue of $22.5 million, marking an 11% increase year-over-year. This growth was driven by the inclusion of Greenbrook’s $4.4 million clinic revenue following the December acquisition and solid performance from NeuroStar system sales and treatment sessions. NeuroStar system revenue was $3.8 million with 46 systems shipped, reflecting a 15% decline from the prior year, partly offset by a 6% increase in average selling price per system. Treatment session revenue declined 14%, primarily due to the reclassification of Greenbrook session revenues into clinic revenue post-acquisition.
Gross margin contracted by over 11 percentage points to 66.2%, reflecting the lower margin profile of Greenbrook’s clinic business, which posted margins in the high 20% range during 2024. Operating expenses rose 28% to $25.8 million, driven by acquisition-related professional fees and the addition of Greenbrook’s operating costs. Despite a wider net loss of $12.2 million, adjusted EBITDA improved to near breakeven, excluding approximately $10.6 million in non-recurring acquisition expenses.
- Revenue Composition Shift: The acquisition introduced a new revenue stream from clinics, diversifying beyond system sales and treatment sessions.
- Margin Pressure: Integration of a lower margin clinic business reduced consolidated gross margins, signaling a near-term trade-off for scale.
- Cost Synergies Realized: Over 90% of the targeted $22 million in annualized cost synergies have been captured ahead of schedule.
Overall, the quarter reflects a transitional phase as Neuronetics integrates Greenbrook, expands its BMP program, and invests in growth initiatives while managing costs and margin pressures.
Executive Commentary
"By combining our innovative technology platform, proven training process, and the BMP program with Greenbrook's established treatment center network, we are positioned to expand patient access to lifesaving mental health treatments while improving our growth and financial position."
Keith Sullivan, President and Chief Executive Officer
"Excluding non-recurring acquisition expenses, EBITDA for the quarter would have been positive $0.1 million, reflecting our operational progress and cost discipline as we integrate Greenbrook and scale our programs."
Steve Furlong, Chief Financial Officer
Strategic Positioning
1. Vertical Integration Through Greenbrook Acquisition
The December 2024 acquisition of Greenbrook TMS transformed Neuronetics into a vertically integrated provider, combining its NeuroStar system sales with direct clinic operations. This enhances control over patient care pathways and revenue diversification, while enabling the deployment of best practices across a broader network of 95 clinics.
2. Expansion of the Better Me Provider (BMP) Program
The BMP program, which sets patient care and responsiveness standards, has expanded to over 350 sites with more than 125 additional sites working to qualify by April 2025. BMP participants treat three times more patients per site than non-participants, demonstrating the program’s effectiveness in driving patient volume and improving referral-to-treatment times by over twofold.
3. Operational Synergies and Cost Optimization
Neuronetics has realized over 90% of a targeted $22 million in annualized cost synergies from the Greenbrook integration, primarily through clinic rationalization and corporate expense reductions. These efficiencies underpin the company’s confidence in achieving cash flow positive status by Q3 2025.
4. Market Expansion via FDA Clearance and Spravato Rollout
The FDA clearance for NeuroStar as a first-line adjunct treatment for adolescents aged 15 to 21 expanded the addressable market by approximately 35%. Concurrently, the rollout of Spravato, a nasal spray treatment for treatment-resistant depression, is progressing, with 63 clinics offering it and 35 utilizing the more profitable buy-and-bill model, expected to extend to 80+ clinics by year-end 2025.
5. Strengthened Financial Position and Capital Flexibility
A recent $18.9 million public offering and refinancing of debt facilities have bolstered Neuronetics’ balance sheet. This capital supports investments in growth initiatives such as BMP expansion, Spravato rollout, and enhanced market analytics, while maintaining a focus on sustainable profitability.
Key Considerations
Neuronetics’ Q4 results and strategic initiatives highlight a company in active transformation, balancing growth and integration challenges:
- Clinic Margin Improvement: Greenbrook’s clinic margins are targeted to rise from the high 20% range to mid-30% in 2025 through clinic rationalization and operational standardization.
- System Utilization Gains: Greenbrook clinics currently average four patients per NeuroStar system daily, with plans to increase toward six, aligning with BMP program partners and driving incremental revenue.
- Patient Access and Referral Efficiency: The integration of automated referral tools and patient education is reducing referral-to-treatment time by approximately 40%, enhancing patient throughput and satisfaction.
- Capital Expenditure Modesty: Supporting Spravato expansion requires modest clinic investments (~$10,000 per clinic), but inventory commitments for medication doses could approach $5 million, managed through distributor credit terms.
- Seasonality and Revenue Sequencing: Q1 typically represents 19-20% of annual revenue, with Q4 being the strongest quarter, reflecting insurance deductible cycles and patient treatment patterns.
Risks
Key risks include the successful execution of integration plans and BMP expansion, potential delays in Spravato buy-and-bill rollout due to payer negotiations, and margin pressures from lower clinic profitability. Additionally, regulatory or reimbursement changes could impact revenue streams. The company’s history of net losses underscores the importance of achieving operational scale and cost efficiencies.
Forward Outlook
For Q1 2025, Neuronetics guides total revenue between $28 million and $30 million. Full-year 2025 revenue is expected between $145 million and $155 million, representing mid-teens growth over pro forma 2024 revenue of approximately $130 million. Gross margin guidance stands at approximately 55%, reflecting clinic integration. Operating expenses are forecasted between $90 million and $98 million, incorporating anticipated cost synergies. Management emphasizes continued scaling of BMP, Spravato rollout, and operational standardization as key growth drivers.
Takeaways
Neuronetics is leveraging its Greenbrook acquisition and BMP program to build a scalable, vertically integrated mental health platform, with a clear path to profitability.
- Integration Drives Scale: The combined entity now operates over 550 clinics, broadening geographic reach and patient access while enabling operational consistency.
- Programmatic Growth Model: BMP’s proven patient volume lift and faster treatment initiation validate the company’s approach to standardizing care and improving outcomes.
- Margin Recovery Potential: While 2024 margins declined due to clinic integration, targeted clinic rationalization and operational improvements are expected to enhance margins in 2025 and beyond.
Conclusion
Neuronetics’ Q4 2024 results mark a pivotal step in its transformation into a vertically integrated neurohealth provider. The company’s strategic acquisitions, program expansions, and financial strengthening position it for sustainable growth and profitability, contingent on successful integration and execution of growth initiatives in 2025.
Industry Read-Through
Neuronetics’ integration of technology with direct clinic operations exemplifies a broader trend in healthcare toward vertically integrated care models that improve patient outcomes and operational efficiencies. The expansion of TMS and adjunctive therapies like Spravato reflects growing acceptance of non-drug mental health treatments. Other players in neurohealth and behavioral health sectors may look to similar acquisitions and programmatic approaches to scale and enhance care delivery. The company’s experience with payer negotiations and inventory management for novel therapeutics provides a case study for managing emerging treatment modalities in a complex reimbursement environment.